New ctDNA data in response monitoring

Thursday, October 14, 2021 Time: 11am ET / 8am PT

Learn about the latest advances in leveraging bespoke ctDNA testing in clinical trials. Find out how Signatera has been applied in early stage and late stage disease. Dive into New published and presented data across multiple tumor types. Discover improvements to clinical trial design with Signatera including: identifying early relapsers, enriching for patients potentially most likely to respond to therapy, accelerating time to trial readout, predicting clinical outcomes as early as 6 weeks into treatment.

Add to calendar